Jim Simons Cardiff Oncology, Inc. Put Options Transaction History
Renaissance Technologies LLC
- $63.6 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CRDF
# of Institutions
86Shares Held
8.48MCall Options Held
798KPut Options Held
39.2K-
Vanguard Group Inc Valley Forge, PA1.92MShares$4.27 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$2.06 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$1.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$1.5 Million0.0% of portfolio
-
Mai Capital Management551KShares$1.22 Million0.03% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $96.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...